Method for treating vascular cutaneous neoplasms

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

 

The invention relates to medicine, to methods of treatment of vascular tumors of the skin, namely flaming nevi and hemangiomas.

Known methods of treatment of vascular skin lesions (see Instruction manual RV Japan TBD Rev 0,1 Medician Systems Yokneam, m, Israel may 1997 ESC Ltd p.77-79), lies in the intense pulsed situalion impact on the blood vessels with energies in the range from 39 to 47 j/cm2. Sweetalba effect on blood vessels causing them thermocoagulation and resorption.

The disadvantages of this method include the possibility of resistance vessels when the vessels cease to perceive sweetalba energy when exposed to them. This leads to interruption of the treatment process at 4-5 months to prevent the occurrence of undesirable side effects and various complications that lengthens the healing process. With the resumption procedures sweetalba impact on vessels begin with more energy. However, excessive energy is not advisable as it may cause thermal burns of the skin, crusting and, as a consequence, education microrobot.

The present invention solves the problem of developing a new method of treatment of vascular tumors of the skin. The technical result consists in effective the capabilities of the proposed method of treatment, consists in obtaining a good therapeutic and cosmetic results after treatment and reducing treatment time due to the use of a combined method effects on vascular lesions of the skin.

This technical result is achieved in that in the method of treatment of vascular tumors of the skin, consisting in intense pulsed situalion impact on the blood vessels with energies in the range from 39 to 47 j/cm2, sweetalba exposure is carried out in two stages, between which after the occurrence of the resistance vessels in the first stage, characterized by the absence of the reaction vessels on sweetalba impact with increased energy and termination change the color of the lesions, perform betteravia daily for 2-3 days with a single dose of 20 Gy, and the second phase svetaefanova exposure start with energy at least 42 j/cm2.

The method of treatment of vascular skin lesions is as follows.

Sweetalba effect on the blood vessels of tumors of the skin is carried out in two phases, with each phase are prepared to treat the surface of the skin, which wipe it with a cleansing lotion and applied to the skin gel that serves as a conductor of light and the cooler for the skin. ASU is estlat intense pulsed sweetalba effect on blood vessels, in the zone of flame nevus or hemangioma.

Sweetalba impact perform double pulse interval between the pulses from 15 to 20 msec. The number of pulses per procedure depends on the area simultaneously captured sweetielouis pulse area of the skin and of the overall size of the treated area of skin. The subsequent procedure is made through 14-21 day after the previous one. The energy with each procedure increases ranging from 39 to 47 j/cm2. After completion of each procedure, remove the gel from the surface of the skin, is applied to the skin cooler and lubricate the skin burns cream. At home within 2-3 days continue applying 2-3 times a day on the treated surface burns cream.

Upon the occurrence of resistance vessels, i.e. when the blood vessels cease to respond to sweetalba impact with increasing energy, which is visually determined by the cessation of the color change neoplasms, suspend the carrying out svetaefanova impact on 2-3 weeks, completing the first stage.

After the break start betterbee, which is done using a set of strontium applicators daily for 2-3 days with a single dose of 20 Gy. The type of applicator is chosen in dependence the value of histogenesis, the location, configuration and size of the skin lesion.

Three weeks after completion of the course betteravia resume sweetalba impact, getting to his second phase, which begins with energy at least 42 j/cm2.

Sweetalba impact during the second stage is carried out in the same sequence as in the implementation of the first phase.

After completing the full course of treatment at home 2-3 times a day on the treated surface, apply burn cream.

Clinical example No. 1. Patient K., born in 1963 On the skin of the lower eyelid of the right eye with the spread on the skin of the right cheek has a vascular education bluish-red, size 5×7 cm, irregular shape. The surface of the formation of a smooth, flat, not rising above the level of the skin. Palpation - soft consistency. Diagnosis: Congenital surface capillary hemangioma of the skin of the right lower eyelid, right cheek.

08.02.2001, commenced treatment: after wiping with a cleansing lotion to the skin in the location of the hemangioma and applied to the gel held intense pulsed sweetalba effect on the blood vessels in the zone of the hemangioma. Sweetalba impact did double pulse with a wavelength of 570 nm, the energy of 39 j/cm2 . The pulse duration of 3 m/sec, the interval between pulses of 15 m/sec. The number of pulses is 5.

01.03.2001, Continued treatment: preparation of the skin before each procedure analogous held before the first procedure. Sweetalba exposure is conducted with the following parameters: double pulse with a wavelength of 550 nm, the energy of 41 j/cm2. the pulse duration of 3 m/sec, the interval between pulses of 15 m/sec, the number of pulses is 5.

21.03.2001, the Treatment continued. Compared with the previous procedure has changed only energy, which is equal to 42 j/cm2.

11.04.2001, the Treatment continued. In the fourth procedure, compared with the previous increased energy when situalion impact the value of its 43 j/cm2. The other parameters remained unchanged.

08.05.2001, During this procedure, the first impulse was carried out with an energy of 44 j/cm2the second and third energy 44,5 j/cm2and the fourth and the fifth with an energy of 45 j/cm2. All other parameters are not changed and remained the same as in the previous procedures.

29.05.2001, Sweetalba effect when this procedure is carried out five double pulses with a wavelength of 550 nm, as in the previous procedures, energy 46 j/cm2the pulse duration remained unchanged, and the interval between pulses comp the fork 12 msec.

19.06.2001, Seventh procedure carried out with increased energy to 47 j/cm2and a reduced interval between pulses up to 10 msec.

10.07.2001, In this procedure, energy is also used was 47 j/cm2as in the implementation of the previous and this procedure did not change the color of the hemangioma, skin did not react to sweetalba impact: no redness, no reaction vessels. Therefore, the conclusion about the occurrence of resistance vessels, and then three weeks later began to perform betterbee.

30.07.2001, For betteravia used the kit strontium applicators. Type applicator was chosen depending on the location, configuration and size of the skin lesion. Course betteravia consisted of daily for two days of sessions irradiation with a single dose of 20 Gy. After the treatment was observed severe reaction in the form of dry epidermitis.

21.08.2001, i.e. three weeks after completion of the course betterbee, resumed second stage svetaefanova impact. Sweetalba impact did double pulse with a wavelength of 550 nm, the energy of 43 j/cm2. The pulse duration of 3 m/sec, the interval between pulses 15 msec. The number of pulses is 5.

04.09.2001, the Treatment continued. Compared with the previous procedure, use the used energy 44 j/cm 2. The other parameters remained unchanged.

Examination of the patient conducted after each procedure, showed the completion of treatment, as a result of the combined effect of the hemangioma achieved good therapeutic and cosmetic effect. On the skin of the lower eyelid of the right eye and cheek is marked complete resorption of vascular lesions. The skin has a pale pink color, surface smooth, smooth. Complications after treatment no.

The method of treatment of vascular tumors of the skin, consisting in intense pulsed situalion impact on the blood vessels with energies in the range from 39 to 47 j/cm2, characterized in that sweetalba exposure is carried out in two stages, between which 2-3 weeks after the onset of resistance vessels in the first stage performs betteravia daily for 2-3 days with a single dose of 20 Gy, and then 3 weeks to have a second stage svetaefanova impact with energies ranging from not less than 42 j/cm2.



 

Same patents:

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

The invention relates to medicine, namely to Hepatology

The invention relates to medicine, namely to the field of physiotherapy and can be used for treatment of nervous system diseases of the spine
The invention relates to medicine, and is intended for the treatment of pain syndromes in patients with pathology of the peripheral nervous system

The invention relates to ophthalmology, and can be used to treat the false myopia

The invention relates to medicine, namely to physiotherapy, and can be used in the treatment of periodontitis
The invention relates to medicine, namely to traumatology and orthopedics, and can be used to diagnose areas of articular cartilage affected degenerative-dystrophic process

FIELD: medicine.

SUBSTANCE: method involves preparation dental surface, covering it with 30% aqueous solution of silver nitrate and recovery agent for precipitating insoluble silver salts. Silver salts precipitation is carried out by exposing silver nitrate covering tooth surface with halogen radiation of the kind produced by halogen lamp of 12 W or 75 W having spectral bandwidth of 400…500 nm provided with light guide for concentrating luminous flux for 60 s.

EFFECT: enhanced effectiveness of treatment; localized treatment; reduced risk of complications and stress action upon child.

FIELD: medicine, oncology.

SUBSTANCE: invention relates to a method for treatment of uterus body topically spread cancer involving applying chemotherapy and intrauterus irradiation. Method is carried out by the following manner: at the 1-st day of treatment cyclophosphan is administrated in the dose 1200-1600 mg by interstitial paratumoral route; at the 2-d day cream-like based fluorouracil in the dose 300-550 mg or adriablastin in the dose 20-30 mg is administrated into uterus cavity; on the next day sйance of intracavitary irradiation is carried out in the dose 10 Gr. All these procedures are repeated three times with interval for 6 days. Method provides high topical concentrations of chemopreparations in tumor zone in reducing their adverse toxic effect that results to the curative effect of patients of elderly age with accompanying therapeutic diseases.

EFFECT: improved method for treatment.

1 ex

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with treating patients with uterine cervix cancer with relapses in parametral fiber and in case of no possibility for radical operative interference and effect of previous radiation therapy. During the 1st d of therapy one should intravenously inject 30 mg platidiam incubated for 1 h at 37 C with 150 ml autoblood, during the next 3 d comes external irradiation per 2.6 G-r. During the 5th d of therapy one should introduce the following composition into presacral space: 60 ml 0.5%-novocaine solution, 1 ml hydrocortisone suspension, 2 ml 50%-analgin solution, 1 ml 0.01%-vitamin B12 solution, 1.6 g gentamycine, 800 mg cyclophosphan, 10 mg metothrexate. These curative impacts should be repeated at mentioned sequence four times. The method enables to decrease radiation loading and toxic manifestations of anti-tumor therapy at achieving increased percent of tumor regression.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

The invention relates to medicine, Oncology
The invention relates to medicine, namely to Hepatology

The invention relates to medicine, namely to psychiatry
The invention relates to medicine, namely to Oncology, and can be used in the treatment of vulvar cancer
Up!